SAM
Senzar Asset Management Portfolio holdings
AUM
$34.7M
This Quarter Return
-1.15%
1 Year Return
+0.55%
3 Year Return
-0.75%
5 Year Return
–
10 Year Return
–
AUM
$34.7M
AUM Growth
+$34.7M
(-88%)
Cap. Flow
-$261M
Cap. Flow
% of AUM
-754.3%
Top 10 Holdings %
Top 10 Hldgs %
75.76%
Holding
37
New
6
Increased
–
Reduced
18
Closed
12
Top Buys
| 1 |
RDUS
Radius Health, Inc.
RDUS
|
$1.78M |
| 2 |
Gilead Sciences
GILD
|
$1.58M |
| 3 |
McKesson
MCK
|
$1M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
$534K |
| 5 |
FOMX
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
|
$338K |
Top Sells
| 1 |
AstraZeneca
AZN
|
$24.1M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$19.5M |
| 3 |
Sanofi
SNY
|
$17.4M |
| 4 |
Pfizer
PFE
|
$15.5M |
| 5 |
Viatris
VTRS
|
$14.8M |
Sector Composition
| 1 | Healthcare | 91.91% |
| 2 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Merck
MRK
$210B
| $6.52M | 18.82% | 107,434 -174,986 | -62% | -$10.6M |
|
|
2
Sanofi
SNY
$121B
| $3.07M | 8.87% | 76,836 -434,610 | -85% | -$17.4M |
|
|
3
Viatris
VTRS
$12.3B
| $3.01M | 8.69% | 83,370 -410,450 | -83% | -$14.8M |
|
4
Cigna
CI
$80.3B
| $2.96M | 8.53% | 17,392 -74,408 | -81% | -$12.6M |
|
|
5
AstraZeneca
AZN
$248B
| $2.51M | 7.23% | 71,400 -686,310 | -91% | -$24.1M |
|
|
6
Regeneron Pharmaceuticals
REGN
$61.5B
| $1.8M | 5.2% | 5,220 -56,500 | -92% | -$19.5M |
|
|
RDUS
7
DELISTED
Radius Health, Inc.
RDUS
| $1.78M | 5.15% | +60,521 | New | +$1.78M |
|
|
8
Gilead Sciences
GILD
$140B
| $1.58M | 4.56% | +22,300 | New | +$1.58M |
|
9
CVS Health
CVS
$92.8B
| $1.57M | 4.52% | 24,330 -96,500 | -80% | -$6.21M |
|
|
AGN
10
DELISTED
Allergan plc
AGN
| $1.45M | 4.2% | 8,723 -83,649 | -91% | -$13.9M |
|
|
ALDR
11
DELISTED
Alder Biopharmaceuticals, Inc.
ALDR
| $1.35M | 3.9% | 85,558 -737,332 | -90% | -$11.7M |
|
12
AnaptysBio
ANAB
$569M
| $1.14M | 3.27% | 15,970 -9,230 | -37% | -$656K |
|
|
13
McKesson
MCK
$85.4B
| $1M | 2.89% | +7,500 | New | +$1M |
|
14
Theravance Biopharma
TBPH
$699M
| $621K | 1.79% | 27,397 -160,459 | -85% | -$3.64M |
|
15
MiMedx Group
MDXG
$1.05B
| $543K | 1.57% | 85,050 -817,050 | -91% | -$5.22M |
|
|
16
Alnylam Pharmaceuticals
ALNY
$58.5B
| $534K | 1.54% | +5,425 | New | +$534K |
|
|
ELGX
17
DELISTED
Endologix Inc
ELGX
| $517K | 1.49% | 91,422 -1,225,490 | -93% | -$6.93M |
|
|
CNCE
18
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $502K | 1.45% | 29,821 -169,318 | -85% | -$2.85M |
|
|
ARNA
19
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $485K | 1.4% | 11,123 -116,441 | -91% | -$5.08M |
|
20
TG Therapeutics
TGTX
$4.65B
| $415K | 1.2% | 31,594 -444,324 | -93% | -$5.84M |
|
21
Protagonist Therapeutics
PTGX
$3.67B
| $412K | 1.19% | 61,304 -114,686 | -65% | -$771K |
|
|
FOMX
22
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $338K | 0.98% | +67,429 | New | +$338K |
|
23
United Therapeutics
UTHR
$13.8B
| $297K | 0.86% | 2,625 -44,375 | -94% | -$5.02M |
|
24
Prothena Corp
PRTA
$441M
| $249K | 0.72% | +17,090 | New | +$249K |
|
25
Amgen
AMGN
$155B
| – | – | -59,300 | Closed | -$10.1M |
|